Resource Summary Report

Generated by dkNET on Sep 3, 2026

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb

RRID:AB_331772
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4376, RRID:AB_331772

Antibody Information

URL: http://antibodyregistry.org/AB_331772

Proper Citation: Cell Signaling Technology Cat# 4376, RRID:AB_331772

Target Antigen: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P. Consolidation: AB_2315155.
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb

Description: This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

Target Organism: Human, Rat, Monkey, Zebrafish, Pig, Mouse, Mink, Hamster

Clone ID: 20G11

Defining Citation: PMID:23720424, PMID:24823391, PMID:24437490, PMID:19565663, PMID:23525221

Antibody ID: AB_331772

Vendor: Cell Signaling Technology

Catalog Number: 4376

Alternative Catalog Numbers: 4376S

Record Creation Time: 20231110T042041+0000

Record Last Update: 20260829T042740+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 123 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. Molecular cancer therapeutics, 25(1), 84.

Wetterwald L, et al. (2026) MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion. The Journal of experimental medicine, 223(5).

Chen X, et al. (2026) MiR-1202 increases radioresistance in nasopharyngeal carcinoma by targeting NAIF1/MAPK/ERK pathway. iScience, 29(4), 115135.

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer immunology research, 14(1), 90.

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. Molecular cancer therapeutics, 25(4), 599.

Diaz-Jimenez A, et al. (2026) EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. Cancer discovery, 16(1), 46.

Zhuo M, et al. (2026) A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Cancer cell, 44(6), 1270.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. iScience, 29(7), 116500.

Preissing B, et al. (2026) Light-activated insulin receptor modulates neuronal plasticity and cerebellar-driven behavior. iScience, 29(7), 116615.

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nature communications, 17(1).

Izawa K, et al. (2026) IgE-dependent anaphylaxis is regulated by sphingolipid binding to activating and inhibitory CD300 family members. Cell reports, 45(3), 117054.

Liu Y, et al. (2026) A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells. Cell reports, 45(7), 117668.

Chávez LF, et al. (2025) GEF-H1 drives breast cancer cells to tumor progression. Biochimica et biophysica acta. Molecular basis of disease, 1871(5), 167816.

Nakajima-Koyama M, et al. (2025) The balance between IFN-? and ERK/MAPK signaling activities ensures lifelong maintenance of intestinal stem cells. Cell reports, 44(3), 115286.

Ageta-Ishihara N, et al. (2025) Septin 3 regulates memory and L-LTP-dependent extension of endoplasmic reticulum into spines. Cell reports, 44(3), 115352.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. The Journal of clinical endocrinology and metabolism, 110(4), 991.

Wang Y, et al. (2025) Innate immune and metabolic signals induce mitochondria-dependent membrane lysis via mitoxyperiosis. Cell, 188(25), 7155.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell reports, 44(4), 115541.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. Neoplasia (New York, N.Y.), 67, 101196.

Chronis IB, et al. (2025) The ?2 adrenergic receptor cross-linked interactome identifies 14-3-3 proteins as regulating the availability of signaling-competent receptors. Molecular pharmacology, 107(1), 100005.